Regression of orthotopic brain tumors by cytokine-assisted tumor vaccines primed in the brain

Sheng Hong Tseng, Chia Ling Hsieh, Swei Ming Lin, Lih Hwa Hwang

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

This study investigated the therapeutic effects of a rat glioma cell line, C6, that was engineered to secrete mouse GM-CSF (mGM-CSF) on intracerebral (i.c.) brain tumors. Significant antitumor immunity was induced in rats when the live or irradiated mGM-CSF-secreting tumor vaccine was implanted i.c. The antitumor activity was effective on small tumors and, to a lesser extent, on large tumors or tumors existing in vivo for a longer duration, Immunohistochemical analysis revealed cellular infiltrates (granulocytes, macrophages, and CD4+ and CD8+ T cells) at both the vaccine site and the tumor site, indicating that immune responses were similarly activated when tumor vaccine was inoculated in the brain, as at the subcutis. Additional studies demonstrated that the therapeutic effects of tumor vaccines on the large tumors or the long-existing tumors were enhanced bystrategies such as increasing the dosage of tumor vaccines, using combined vaccines consisting of mGM-CSF and human interleukin-2, or combining tumor vaccine with herpes simplex virus thymidine kinase/ganciclovir treatment. All of the modified strategies yielded synergistic therapeutic effects on the large tumor burdens. The data presented herein suggest that cytokine gene therapy is highly promising for the treatment of i.c. gliomas.

Original languageEnglish
Pages (from-to)302-312
Number of pages11
JournalCancer Gene Therapy
Volume6
Issue number4
Publication statusPublished - 1999
Externally publishedYes

Fingerprint

Cancer Vaccines
Brain Neoplasms
Cytokines
Brain
Therapeutic Uses
Granulocyte-Macrophage Colony-Stimulating Factor
Neoplasms
Glioma
Combined Vaccines
Ganciclovir
Thymidine Kinase
Simplexvirus
Tumor Burden
Granulocytes
Genetic Therapy
Interleukin-2
Immunity
Macrophages
T-Lymphocytes
Cell Line

Keywords

  • Gene therapy
  • Glioma
  • GM-CSF
  • Herpes simplex virus thymidine kinase
  • Interleukin-2
  • Tumor vaccine

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Regression of orthotopic brain tumors by cytokine-assisted tumor vaccines primed in the brain. / Tseng, Sheng Hong; Hsieh, Chia Ling; Lin, Swei Ming; Hwang, Lih Hwa.

In: Cancer Gene Therapy, Vol. 6, No. 4, 1999, p. 302-312.

Research output: Contribution to journalArticle

Tseng, Sheng Hong ; Hsieh, Chia Ling ; Lin, Swei Ming ; Hwang, Lih Hwa. / Regression of orthotopic brain tumors by cytokine-assisted tumor vaccines primed in the brain. In: Cancer Gene Therapy. 1999 ; Vol. 6, No. 4. pp. 302-312.
@article{5eb32a3bbeb64203a1eb9e858565a5cc,
title = "Regression of orthotopic brain tumors by cytokine-assisted tumor vaccines primed in the brain",
abstract = "This study investigated the therapeutic effects of a rat glioma cell line, C6, that was engineered to secrete mouse GM-CSF (mGM-CSF) on intracerebral (i.c.) brain tumors. Significant antitumor immunity was induced in rats when the live or irradiated mGM-CSF-secreting tumor vaccine was implanted i.c. The antitumor activity was effective on small tumors and, to a lesser extent, on large tumors or tumors existing in vivo for a longer duration, Immunohistochemical analysis revealed cellular infiltrates (granulocytes, macrophages, and CD4+ and CD8+ T cells) at both the vaccine site and the tumor site, indicating that immune responses were similarly activated when tumor vaccine was inoculated in the brain, as at the subcutis. Additional studies demonstrated that the therapeutic effects of tumor vaccines on the large tumors or the long-existing tumors were enhanced bystrategies such as increasing the dosage of tumor vaccines, using combined vaccines consisting of mGM-CSF and human interleukin-2, or combining tumor vaccine with herpes simplex virus thymidine kinase/ganciclovir treatment. All of the modified strategies yielded synergistic therapeutic effects on the large tumor burdens. The data presented herein suggest that cytokine gene therapy is highly promising for the treatment of i.c. gliomas.",
keywords = "Gene therapy, Glioma, GM-CSF, Herpes simplex virus thymidine kinase, Interleukin-2, Tumor vaccine",
author = "Tseng, {Sheng Hong} and Hsieh, {Chia Ling} and Lin, {Swei Ming} and Hwang, {Lih Hwa}",
year = "1999",
language = "English",
volume = "6",
pages = "302--312",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Regression of orthotopic brain tumors by cytokine-assisted tumor vaccines primed in the brain

AU - Tseng, Sheng Hong

AU - Hsieh, Chia Ling

AU - Lin, Swei Ming

AU - Hwang, Lih Hwa

PY - 1999

Y1 - 1999

N2 - This study investigated the therapeutic effects of a rat glioma cell line, C6, that was engineered to secrete mouse GM-CSF (mGM-CSF) on intracerebral (i.c.) brain tumors. Significant antitumor immunity was induced in rats when the live or irradiated mGM-CSF-secreting tumor vaccine was implanted i.c. The antitumor activity was effective on small tumors and, to a lesser extent, on large tumors or tumors existing in vivo for a longer duration, Immunohistochemical analysis revealed cellular infiltrates (granulocytes, macrophages, and CD4+ and CD8+ T cells) at both the vaccine site and the tumor site, indicating that immune responses were similarly activated when tumor vaccine was inoculated in the brain, as at the subcutis. Additional studies demonstrated that the therapeutic effects of tumor vaccines on the large tumors or the long-existing tumors were enhanced bystrategies such as increasing the dosage of tumor vaccines, using combined vaccines consisting of mGM-CSF and human interleukin-2, or combining tumor vaccine with herpes simplex virus thymidine kinase/ganciclovir treatment. All of the modified strategies yielded synergistic therapeutic effects on the large tumor burdens. The data presented herein suggest that cytokine gene therapy is highly promising for the treatment of i.c. gliomas.

AB - This study investigated the therapeutic effects of a rat glioma cell line, C6, that was engineered to secrete mouse GM-CSF (mGM-CSF) on intracerebral (i.c.) brain tumors. Significant antitumor immunity was induced in rats when the live or irradiated mGM-CSF-secreting tumor vaccine was implanted i.c. The antitumor activity was effective on small tumors and, to a lesser extent, on large tumors or tumors existing in vivo for a longer duration, Immunohistochemical analysis revealed cellular infiltrates (granulocytes, macrophages, and CD4+ and CD8+ T cells) at both the vaccine site and the tumor site, indicating that immune responses were similarly activated when tumor vaccine was inoculated in the brain, as at the subcutis. Additional studies demonstrated that the therapeutic effects of tumor vaccines on the large tumors or the long-existing tumors were enhanced bystrategies such as increasing the dosage of tumor vaccines, using combined vaccines consisting of mGM-CSF and human interleukin-2, or combining tumor vaccine with herpes simplex virus thymidine kinase/ganciclovir treatment. All of the modified strategies yielded synergistic therapeutic effects on the large tumor burdens. The data presented herein suggest that cytokine gene therapy is highly promising for the treatment of i.c. gliomas.

KW - Gene therapy

KW - Glioma

KW - GM-CSF

KW - Herpes simplex virus thymidine kinase

KW - Interleukin-2

KW - Tumor vaccine

UR - http://www.scopus.com/inward/record.url?scp=0033159136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033159136&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 302

EP - 312

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 4

ER -